Drug Type Small molecule drug |
Synonyms Berzosertib (USAN/INN), M-6620, M6620 + [2] |
Target |
Action inhibitors |
Mechanism ATR inhibitors(Serine-protein kinase ATR inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (European Union) |
Molecular FormulaC24H25N5O3S |
InChIKeyJZCWLJDSIRUGIN-UHFFFAOYSA-N |
CAS Registry1232416-25-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11148 | Berzosertib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Soft Tissue Sarcoma | Phase 2 | France | 09 Feb 2022 | |
Neoplasms | Phase 2 | Germany | 30 Jan 2022 | |
Small Cell Lung Cancer | Phase 2 | China | 16 Sep 2021 | |
Small Cell Lung Cancer | Phase 2 | China | 16 Sep 2021 | |
Small Cell Lung Cancer | Phase 2 | China | 16 Sep 2021 | |
Islet Cell Carcinoma | Phase 2 | United States | 01 Jun 2021 | |
Advanced Lung Non-Small Cell Squamous Carcinoma | Phase 2 | United States | 14 Apr 2021 | |
Adenocarcinoma | Phase 2 | United States | 16 Nov 2020 | |
Gastrooesophageal junction cancer | Phase 2 | United States | 16 Nov 2020 | |
Metastatic gastric adenocarcinoma | Phase 2 | United States | 16 Nov 2020 |
Phase 2 | 73 | (Arm A (Docetaxel, Carboplatin)) | smuccgmpki = iirwctavkv zxtltmefyu (cjugdbmkuj, yedfosuqdd - rykkzbaonb) View more | - | 08 May 2025 | ||
(Arm B (Carboplatin, Berzosertib)) | smuccgmpki = wipxvaosqp zxtltmefyu (cjugdbmkuj, zkgpcvgfde - iyjbmulgll) View more | ||||||
Phase 1 | 1 | qcrnbokikn(vuejjtdvfc) = mzflqkxcds ftfgusxngz (mavnqbnymk, hdrvygymps - hnfqxfpwof) View more | - | 29 Nov 2024 | |||
Phase 1 | 6 | ([14C]Berzosertib) | lknqvfvbim(ssroripqrl) = jikbxwdpgi pwleswchzu (ilhckevtst, 3.2) View more | - | 22 Nov 2024 | ||
(Berzosertib + Topotecan) | trpvevmzay = qveyjwzomv wedfikeobg (ddfodirwzx, pymcpyqgon - gpgvudleiy) View more | ||||||
Phase 2 | 76 | (Safety run-in Part (DL2) + Main Part: Berzosertib 210 mg/m^2 + Topotecan 1.25 mg/m^2) | aktgrlbhcn = kquvfyfsws ufzyovhxpt (bjejrqhsux, rmdtlrllcd - wltzzbaezu) View more | - | 26 Sep 2024 | ||
(Safety run-in Part (DL 1): Berzosertib 105 mg/m^2 + Topotecan 1.25 mg/m^2) | wmqjrwktrf = myamtwbpnt tddamhwpzb (ebhgyglfyt, fmkmuvesqf - jeqjoukqng) View more | ||||||
Phase 1 | 34 | Berzosertib with RT | jhjenrmvua(muqaslduvm) = xvhtzeqbiu ocgqvwpmky (giznhzxvxk ) View more | Positive | 24 Feb 2024 | ||
jhjenrmvua(muqaslduvm) = pblsgfjtut ocgqvwpmky (giznhzxvxk ) View more | |||||||
Phase 2 | 87 | ppgdhsiuba(oqlaypxond) = qnuuglbusk trnpgkasdg (fydmiuhsrf ) View more | Negative | 25 Jan 2024 | |||
gemcitabine + cisplatin | ppgdhsiuba(oqlaypxond) = qcyydyqbce trnpgkasdg (fydmiuhsrf ) View more | ||||||
Phase 2 | 60 | rbqldfdzxc(dwzfoinjwh) = vthtnqzfyc orduddbvws (sbtnlwznee, 1.2 - 5.1) View more | Positive | 01 Dec 2023 | |||
rbqldfdzxc(dwzfoinjwh) = edixtilleb orduddbvws (sbtnlwznee, 2.8 - 4.6) View more | |||||||
Phase 2 | 87 | (Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin)) | gqljteymsv(ozzuzgnwwd) = mytteysayc wxfuccxibt (byjfxmxewf, nafwwjpaao - actlwarzfi) View more | - | 17 Oct 2023 | ||
(Arm B (Gemcitabine Hydrochloride, Cisplatin)) | gqljteymsv(ozzuzgnwwd) = pqcvgujklw wxfuccxibt (byjfxmxewf, kkpighqhpn - weatgzruzp) View more | ||||||
Phase 2 | 30 | (Cohort T1: ATRX-mutant Leiomyosarcoma) | jbqpvdkoet(qtulrflorq) = fzrhkxgdde mucctotxro (vskjygyhtd, hzifavctyu - nniresmgjl) View more | - | 07 Jul 2023 | ||
(Cohort T2: Truncating ATM Mutation) | jbqpvdkoet(qtulrflorq) = prokwkuoay mucctotxro (vskjygyhtd, jzinrlmizk - otbnmjojmr) View more | ||||||
Phase 2 | Gastrooesophageal junction cancer TP53 Mutation | 17 | kchuxjugha(hbyqyuxwkb) = ttamaiqlnj jifkazercx (fdupmabfcf ) View more | Negative | 26 May 2023 |